Bayer and Loxo Oncology have won FDA approval for the Vitrakvi® (larotrectinib), the first cancer treatment with a tumor-agnostic indication at the time of initial authorization, with approval based on mutation type rather than on where in the body the tumor originated. The first ever oral tyrosine kinase (TRK) inhibitor, Vitrakvi is indicated for adults […]
The post Bayer, Loxo Win FDA Approval for Tumor-Agnostic Cancer Drug Vitrakvi appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Bayer, Loxo Win FDA Approval for Tumor-Agnostic Cancer Drug Vitrakvi